Fundraising

FLS XII will primarily invest in early-stage private biopharmaceutical companies.

This fundraising brings Yaletown's total active funds under management to approximately $600 million.

Oak HC/FT Partners closed its previous fund at $1.94 billion in July 2022.

WovenEarth Ventures, which raised $152m for its debut fund of funds last year, is targeting $300m for its second effort.

BlackWood made its first close in April 2023.

The growth-stage tech investor, which is targeting $225m for its fifth flagship, uses a broad range of both primary and secondary deal structures to support its portfolio and LPs.

Omega Fund VIII will invest in life sciences companies in the US and Europe that target severe, unmet medical needs.

Brio developed its LP management software in-house at Brightspark before spinning out and raising a seed round earlier this year.

The target is undisclosed.

Three years ago, Cambrian closed on a debut fund of $20 million.